Free tool
FAERS Monitor: Basaglar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 205692 or its brand name (Basaglar, Insulin Glargine). Reports on generic versions are filed under their own applications.
Reports
45,246
Serious
26,158
58% of reports
Hospitalization
14,746
Death reported
3,004
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood glucose increased7,220
- incorrect dose administered2,585
- drug ineffective2,134
- visual impairment2,008
- hypoglycaemia1,944
- blood glucose decreased1,684
- nausea1,591
- accidental underdose1,544
- diarrhoea1,438
- injection site pain1,423
- fatigue1,345
- inappropriate schedule of product administration1,306
- dyspnoea1,288
- off label use1,252
- vomiting1,234
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 99 |
| 2005 | 108 |
| 2006 | 89 |
| 2007 | 111 |
| 2008 | 169 |
| 2009 | 191 |
| 2010 | 299 |
| 2011 | 360 |
| 2012 | 264 |
| 2013 | 403 |
| 2014 | 423 |
| 2015 | 619 |
| 2016 | 740 |
| 2017 | 2,296 |
| 2018 | 4,877 |
| 2019 | 5,649 |
| 2020 | 4,766 |
| 2021 | 4,528 |
| 2022 | 4,659 |
| 2023 | 3,922 |
| 2024 | 4,035 |
| 2025 | 3,981 |
| 2026 | 2,657 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,008,913 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| accidental underdoseSignal | 1,544 | 55.7 | 52.9 | 74,096 |
| hypoglycaemiaSignal | 1,944 | 19.4 | 18.5 | 32,563 |
| blood glucose increasedSignal | 7,220 | 18.5 | 18.1 | 115,848 |
| blood glucose decreasedSignal | 1,684 | 16.9 | 16.1 | 24,280 |
| visual impairmentSignal | 2,008 | 7.6 | 7.3 | 11,461 |
| incorrect dose administeredSignal | 2,585 | 5.3 | 5.1 | 9,042 |
| inappropriate schedule of product administrationSignal | 1,306 | 3.4 | 3.2 | 2,196 |
| injection site painSignal | 1,423 | 2.2 | 2.1 | 896 |
| vomiting | 1,234 | 1.2 | 1.2 | 50 |
| dyspnoea | 1,288 | 1.1 | 1.0 | 4 |
| diarrhoea | 1,438 | 1.0 | 1.0 | 2 |
| nausea | 1,591 | 0.9 | 0.9 | 8 |
| fatigue | 1,345 | 0.8 | 0.8 | 67 |
| drug ineffective | 2,134 | 0.8 | 0.7 | 185 |
| off label use | 1,252 | 0.7 | 0.6 | 221 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.